Stockscreener 앱 받기
0.00
100.00%
-0.0549
Adaptimmune Therapeutics Plc Adr 주식(ADAP)의 최신 뉴스
ADAPY Price History for Adaptimmune Therapeutics Plc ADR Stock - Barchart.com
How Adaptimmune Therapeutics plc (Common Stock) (473A) stock performs during market turbulence2025 EndofYear Setup & Technical Pattern Based Signals - newser.com
Adaptimmune Therapeutics plc (ADAPY) stock price, news, quote and history - Yahoo Finance Singapore
Adaptimmune Therapeutics PLC (ADAPY) Stock PDF (Updated: 2025/11/05) - GuruFocus
Adaptimmune Therapeutics PLC Sponsored ADR Financial Disclosures & SEC Filings - TradingView
ADAP Stock Price | Automatic Data Processing Inc. Stock Quote (Mexico) - MarketWatch
Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback? - ts2.tech
Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer - GlobeNewswire Inc.
ADAP Stock Price, Forecast & Analysis | ADAPTIMMUNE THERAPEUTICS-ADR (NASDAQ:ADAP) - Chartmill
Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Adaptimmune stock plunges after announcing Nasdaq delisting plans By Investing.com - Investing.com Philippines
Adaptimmune stock plunges after announcing Nasdaq delisting plans - Investing.com India
Adaptimmune to delist from Nasdaq amid cost-cutting efforts - Investing.com
Pre-Market Movers: MIRA, ADAP, GNPX Swing Big - RTTNews
Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp? - ts2.tech
Take off with Adaptimmune Therapeutics Plc ADR (ADAP): Get ready for trading - Setenews
Pre-Market Titans: TTRX, BJDX & UPC Set The Pace - RTTNews
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real? - ts2.tech
Morning Market Movers: FEMY, PALI, COSM, Seeing Big Swings - RTTNews
Adversity is less terrifying than hope: Adaptimmune Therapeutics Plc ADR (ADAP) - setenews.com
Adaptimmune Granted Exception Period by Nasdaq Panel - The Globe and Mail
Morning Market Movers: MRM, LEXX, WOLF See Big Swings - RTTNews
Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC - Yahoo Finance
Must-Watch Streaming Stocks Poised to Gain From Content Boom - Yahoo Finance
Is Hesai Group Sponsored ADR (HSAI) Outperforming Other Auto-Tires-Trucks Stocks This Year? - Yahoo Finance
Lenovo Finds 65% of IT Leaders Admit Their Defenses Can’t Withstand AI Cybercrime - Yahoo Finance
Why the Market Dipped But Li Auto Inc. Sponsored ADR (LI) Gained Today - Yahoo Finance
What Does Wall Street Think About Li Auto Inc. (LI)? - Yahoo Finance
Vestas Wind Systems AS ADR (VWDRY) Wind Turbines Orders on the Rise - Yahoo Finance
The Zacks Analyst Blog Highlights Walmart, Alibaba, Shell, Omega Flex and Weyco - Yahoo Finance
Investors Take Advantage Of 15.76% Gain In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - stocksregister.com
What Is Going On With Top KingWin Ltd (NASDAQ: WAI)? - stocksregister.com
Rio Tinto plc ADR Common Stock (RIO) Restructures to Focus on Profitable Assets - Yahoo Finance
Zacks.com featured highlights include Halozyme Therapeutics, Phibro, Leidos and PDD Holdings - Yahoo Finance
Adaptimmune Therapeutics CFO Wood sells $950 in shares - Investing.com
Nio Inc. ADR (NIO) Upgraded to ‘Overweight’ at JPMorgan on Strong Vehicle Demand - Yahoo Finance
Earnings call transcript: Adaptimmune Q2 2025 shows revenue beat, stock dips - Investing.com
Adaptimmune director Behbahani sells shares worth $229,171 - Investing.com
Are Investors Undervaluing ENGIESponsored ADR (ENGIY) Right Now? - Yahoo Finance
Adaptimmune Sales Jump 59 Percent - sharewise.com
Is Piedmont Lithium Inc.Sponsored ADR (PLL) Stock Outpacing Its Basic Materials Peers This Year? - Yahoo Finance
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - Yahoo Finance
Wall Street Today: Dow, Nasdaq, S&P 500 open higher as investors focus on optimism over potential US Fed rate cut - Mint
Ecor1 capital sells Adaptimmune Therapeutics (ADAP) shares for $6.89m By Investing.com - Investing.com India
Ecor1 capital sells Adaptimmune Therapeutics (ADAP) shares for $6.89m - Investing.com
Adaptimmune stock rating downgraded by H.C. Wainwright after asset sale - Investing.com
Adaptimmune Therapeutics stock plunges after selling cell therapy assets - Investing.com
XPeng Inc. Sponsored ADR (XPEV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect - Yahoo Finance
Mizuho downgrades Adaptimmune stock on solvency concerns - Investing.com
Best Momentum Stocks to Buy for June 12th - Yahoo Finance
KANZHUN LIMITED Sponsored ADR (BZ) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105 - Yahoo Finance
Grammy Award Winning Artist Knows How Math Can Help Prevent Cancer - Yahoo Finance
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy - Investing.com
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy - Investing.com
Adaptimmune Therapeutics Amends Loan Agreement - Investing.com
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating - Investing.com
UPDATE: Adaptimmune, after bringing cell therapy to market, questions viability and defunds 2 preclinical programs - Fierce Biotech
Alcohol company stocks are falling after Trump threatened tariffs on Europe's spirits - Yahoo Finance
Adaptimmune therapeutics CEO Adrian Rawcliffe sells shares worth $34,639 - Investing.com
Adaptimmune faces Nasdaq delisting over share price - Investing.com
Painful week for retail investors invested in Adaptimmune Therapeutics plc (NASDAQ:ADAP) after 11% drop, institutions also suffered losses - Sahm
Rio Tinto's Share Price Increases 10% in a Week: How to Play It? - Yahoo Finance
Adaptimmune finalizes settlement with Genentech - Investing.com
Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 11% this week, taking three-year losses to 80% - Sahm
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor - Quantisnow
Adaptimmune and Galapagos partner on cancer therapy - Investing.com
Adaptimmune shares hold at $1 target by Barclays on FDA outlook - Investing.com
Adaptimmune (ADAP) Down on End of Collaboration With Roche - Yahoo Finance
New Strong Buy Stocks for March 15th - Yahoo Finance
2.90%
2.73%
자본화:
|
볼륨(24시간):